ResMed director Peter Farrell sells $494,640 in stock

ResMed's Chairman Emeritus, Peter Farrell, sold 2,000 shares at $247.32 on June 4, 2025, under a pre-established 10b5-1 trading plan, retaining 69,218 shares. This sale coincides with recent analyst activity following ResMed's Q3 FY25 results, including price target increases from Citi (to AUD45.00) and UBS ($285.00) reflecting optimism around earnings and potential market impacts from new treatments, balanced by Hold ratings from Stifel ($240.00) and RBC Capital ($255.00) amid concerns about GLP-1 medications and market challenges.

Analysis

Peter C. Farrell, Chairman Emeritus and Director at ResMed Inc. (NYSE:RMD), executed a sale of 2,000 common shares on June 4, 2025, at $247.32 per share, realizing $494,640. This transaction was conducted under a pre-established Rule 10b5-1 trading plan adopted in May 2024, leaving Farrell with 69,218 shares. This planned insider disposition coincides with a period of active analyst commentary following ResMed's third-quarter fiscal year 2025 results. Optimism is evident from Citi, which raised its stock price target to AUD45.00 and maintained a Buy rating, citing improved earnings per share (EPS) projections for fiscal years 2025 to 2027. UBS also reaffirmed a Buy rating with a $285.00 price target, highlighting the potential positive market impact from Apnimed’s new treatment for obstructive sleep apnea. However, caution is present; Stifel maintained a Hold rating with a $240.00 target, expressing concerns regarding the potential adverse effects of GLP-1 medications on ResMed's future growth. RBC Capital adjusted its price target to $255.00, maintaining a Sector Perform rating, and noted the favorable impact of U.S. tariff exemptions on the company’s financials. This range of analyst actions underscores a nuanced outlook for ResMed, balancing positive earnings momentum and strategic opportunities against potential market disruptions and competitive pressures.

Key Decisions for Investors

• Investors should monitor the market adoption and competitive impact of Apnimed’s new sleep apnea treatment, as well as ResMed's strategic responses, to gauge shifts in market dynamics.
• It is crucial to evaluate the evolving risk posed by GLP-1 medications to ResMed's core patient population and assess its potential impact on long-term revenue and growth forecasts.
• Consider the balance between ResMed's improved EPS outlook and benefits from U.S. tariff exemptions against the mixed analyst sentiment and the context of the pre-planned insider share sale when making investment decisions.